Citations

Showing 10 of 108119 citations.

Determination of the Velocity of Sound in a Gas; Application to Analysis of Mixtures of Helium, Oxygen and Nitrogen
Dublin, William B., Boothby, Walter M., Williams, Marvin M. D.

Mayo Clinic

Science | October 7, 2021 | Volume: 90 | Issue: 2339 | Pages: 399-400

10.1126/science.90.2339.399-b Get It

P076 Sleep Staging Agreement Between Polysomnography and Sleep Profiler in Isolated REM Sleep Behavior Disorder
Levendowski, Daniel J. , Lee‐Iannotti, Joyce , Guevarra, C, Timm, Paul, Angel, E, Mazeika, Gandis, Shprecher, David , Angel, Elise, Louis, Erik K. St.

Mayo Clinic

SLEEP Advances | October 7, 2021 | Volume: 2 | Issue: Supplement_1 | Pages: A45-A46

10.1093/sleepadvances/zpab014.120 Get It

Abstract Purpose Evaluate the sleep staging agreement between polysomnography (PSG) and Sleep Profiler (SP) in patients with suspected isolated REM-sleep-behavior-disorder. Methods Twenty-six patients with reported dream-enactment-behavior (Site1=16, Site2=10; 27% women; age 64±13 years) underwent a diagnostic PSG with simultaneously recorded SP. A registered sleep-technologist at each site performed PSG-staging, while SP was auto-staged and technically reviewed/edited. Across technicians, the initial staging was blinded. Site1 then performed unblinded restaging of PSG=N3(N2) vs. SP=N2(N3) epochs, while Site2 conducted a blinded, carefully-targeted restaging of N3. Statistics included Cohen’s kappa and Chi-square analyses. Results Agreement between SP and Site1 vs. Site2 were significantly different for Wake (kappa:Site1=0.816;Site2=0.650;combined=0.736), stage N1 (kappa:Site1=0.149;Site2=0.228;combined=0.188), stage N2 (kappa:Site1=0.632;Site2=0.718;combined=0.659), stage N3 (kappa:Site1=0.715;Site2=0.368;combined=0.525) and REM (kappa:Site1=0.827;Site2=0.719;combined=0.766)(all P<0.001). After restaging of N3, the kappa values improved at Site1 (unblinded:N2=0.659/N3=0.883) and Site2 (blinded:N2=0.775/N3=0.736)(combined:N2=0.735/N3=0.851). The proportion of PSG-epochs restaged from N3 to N2 was 17% at Sites1 and 38% at Site2 (P<0.001), while Site1 had fewer remaining PSG=N3 vs. SP=N2 conflicts (5.6% vs. 20.8%, P<0.001). Compared to Site2, Site1 had a superior: REM kappa due to fewer SP=N2 disagreements (8.5% vs. 16.8%, P<0.001), and Wake kappa resulting from fewer SP=N1 (6.6 vs. 15.6%, P<0.001) and SP=N2 conflicts (5.9 vs. 12.0%, P<0.001). Conversely, the Site1 N1 kappa was inferior due to greater SP=wake disagreement (41.6% vs. 19.8%, P<0.001). Discussion N3 was excessively stage by both PSG technicians before restaging. At Site1, Wake, N3, and REM had almost-perfect-agreement with SP, while N2 had substantial-agreement. At Site2 and across-site, substantial-agreement was observed for Wake, N2, N3, and REM.
Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients
Park, Sookhyeon , Guo, Kexin , Heilman, Raymond L. , Poggio, Emilio D. , Kurian, Sunil M. , Kleiboeker, Steve, Weems, Juston C. , Holman, John , Zhao, Lihui , Brietigam, S., Rebello, Christabel , Friedewald, John J. , Friedewald, John J , Kurian, Sunil , Taber, David J. , Marsh, Christopher L. , Kleiboeker, Steve , Sinha, Rohita , Abecassis, Michael M.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | October 7, 2021 | Volume: 16 | Issue: 10 | Pages: 1539-1551

10.2215/cjn.05530421 | PMID 34620649 Get It

Background and objectives Subclinical acute rejection is associated with poor outcomes in kidney transplant recipients. As an alternative to surveillance biopsies, noninvasive screening has been established with a blood gene expression profile. Donor-derived cellfree DNA (cfDNA) has been used to detect rejection in patients with allograft dysfunction but not tested extensively in stable patients. We hypothesized that we could complement noninvasive diagnostic performance for subclinical rejection by combining a donor-derived cfDNA and a gene expression profile assay. Design, setting, participants, & measurements We performed a post hoc analysis of simultaneous blood gene expression profile and donor-derived cfDNA assays in 428 samples paired with surveillance biopsies from 208 subjects enrolled in an observational clinical trial (Clinical Trials in Organ Transplantation-08). Assay results were analyzed as binary variables, and then, their continuous scores were combined using logistic regression. The performance of each assay alone and in combination was compared. Results For diagnosing subclinical rejection, the gene expression profile demonstrated a negative predictive value of 82%, a positive predictive value of 47%, a balanced accuracy of 64%, and an area under the receiver operating curve of 0.75. The donor-derived cfDNA assay showed similar negative predictive value (84%), positive predictive value (56%), balanced accuracy (68%), and area under the receiver operating curve (0.72). When both assays were negative, negative predictive value increased to 88%. When both assays were positive, positive predictive value increased to 81%. Combining assays using multivariable logistic regression, area under the receiver operating curve was 0.81, significantly higher than the gene expression profile ( P <0.001) or donor-derived cfDNA alone ( P =0.006). Notably, when cases were separated on the basis of rejection type, the gene expression profile was significantly better at detecting cellular rejection (area under the receiver operating curve, 0.80 versus 0.62; P =0.001), whereas the donor-derived cfDNA was significantly better at detecting antibody-mediated rejection (area under the receiver operating curve, 0.84 versus 0.71; P =0.003). Conclusions A combination of blood-based biomarkers can improve detection and provide less invasive monitoring for subclinical rejection. In this study, the gene expression profile detected more cellular rejection, whereas donor-derived cfDNA detected more antibody-mediated rejection.
Radiology Implementation Considerations for Artificial Intelligence (AI) Applied to COVID-19, From the AJR Special Series on AI Applications
Mei, Xueyan , Bernheim, Adam , Chung, Michael , Steinberger, Sharon , Kalpathy–Cramer, Jayashree , Little, Brent P. , Li, Matthew , Chang, Ken

Mayo Clinic

American Journal of Roentgenology | October 7, 2021 | Volume: 219 | Issue: 1 | Pages: 15-23

10.2214/ajr.21.26717 | PMID 34612681 Get It

Serrated lesions and adenomas in colonoscopic surveillance: additive or exponential?
East, James E. , East, James E

Mayo Clinic

Gut | October 7, 2021 | Volume: 71 | Issue: 10 | Pages: 1932-1933

10.1136/gutjnl-2021-325772 | PMID 34620685 Get It

Inclusion body myositis: correlation of clinical outcomes with histopathology, electromyography and laboratory findings
Pinto, Marcus Vinícius , Laughlin, Ruple S. , Mandrekar, Jay , Naddaf, Elie , Pinto, Marcus V , Naddaf, Elie , Klein, Christopher J.

Mayo Clinic

Rheumatology | October 7, 2021 | Volume: 61 | Issue: 6 | Pages: 2504-2511

10.1093/rheumatology/keab754 | PMID 34617994 Get It

Abstract Objective To determine whether histopathological, electromyographic and laboratory markers correlate with clinical measures in inclusion body myositis (IBM). Methods We reviewed our electronic medical records to identify patients with IBM according to European Neuromuscular Center (ENMC) 2011 criteria, seen between 2015 and 2020. We only included patients who had a muscle biopsy and needle electromyography (EMG) performed on the same muscle (opposite or same side). We used a detailed grading system [0 (normal) to 4 (severe)] to score histopathological and EMG findings. Clinical severity was assessed by the modified Rankin scale (mRS), muscle strength sum score (SSS), quadriceps strength and severity of dysphagia on swallow evaluation. Serum markers of interest were creatine kinase level and cN-1A antibodies. Results We included 50 IBM patients, with a median age of 69 years; 64% were males. Median disease duration at diagnosis was 51 months. On muscle biopsy, endomysial inflammation mainly correlated with dysphagia, and inversely correlated with mRS. Vacuoles and congophilic inclusions did not correlate with any of the clinical measures. On EMG, the shortness of motor un it potential (MUP) duration correlated with all clinical measures. Myotonic discharges, and not fibrillation potentials, correlated with the severity of inflammation. Serum markers did not have a statistically significant correlation with any of the clinical measures. Conclusions Dysphagia was the main clinical feature of IBM correlating with endomysial inflammation. Otherwise, inclusion body myositis clinical measures had limited correlation with histopathological features in this study. The shortness of MUP duration correlated with all clinical measures.
Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis
Berti, Alvise , Hillion, Sophie , Hummel, Amber M., Son, Young Min , Chriti, Nedra, Peikert, Tobias, Carmona, Eva M. , Abdulahad, Wayel H. , Heeringa, Peter , Harris, Kristina M. , Clair, E. William St. , Brunetta, Paul , Langford, Carol A. , Kallenberg, Cees G. M., Stone, John H. , Grandi, Guido , Cornec, Divi, Carmona, Eva M , Berti, Alvise , Fervenza, Fernando C. , Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Spiera, Robert , Sun, Jie , Pers, Jacques-Olivier , Specks, Ulrich , Cornec, Divi

Mayo Clinic

JCI Insight | October 7, 2021 | Volume: 6 | Issue: 22 | Pages: No page available

10.1172/jci.insight.150999 | PMID 34618687 Get It

BACKGROUND Little is known about the autoreactive B cells in antineutrophil cytoplasmic antibody–associated (ANCA-associated) vasculitis (AAV). We aimed to investigate tolerance checkpoints of circulating antigen-specific proteinase 3–reactive (PR3 + ) B cells. METHODS Multicolor flow cytometry in combination with bioinformatics and functional in vitro studies were performed on baseline samples of PBMCs from 154 well-characterized participants of the RAVE trial (NCT00104299) with severely active PR3-AAV and myeloperoxidase-AAV (MPO-AAV) and 27 healthy controls (HCs). Clinical data and outcomes from the trial were correlated with PR3 + B cells (total and subsets). RESULTS The frequency of PR3 + B cells among circulating B cells was higher in participants with PR3-AAV (4.77% median [IQR, 3.98%–6.01%]) than in participants with MPO-AAV (3.16% median [IQR, 2.51%–5.22%]) and participants with AAV compared with HCs (1.67% median [IQR, 1.27%–2.16%], P < 0.001 for all comparisons), implying a defective central tolerance checkpoint in patients with AAV. Only PBMCs from participants with PR3-AAV contained PR3 + B cells capable of secreting PR3-ANCA IgG in vitro, proving they were functionally distinct from those of participants with MPO-AAV and HCs. Unsupervised clustering identified subtle subsets of atypical autoreactive PR3 + memory B cells accumulating through the maturation process in patients with PR3-AAV. PR3 + B cells were enriched in the memory B cell compartment of participants with PR3-AAV and were associated with higher serum CXCL13 levels, suggesting an increased germinal center activity. PR3 + B cells correlated with systemic inflammation (C-reactive protein and erythrocyte sedimentation rate, P < 0.05) and complete remission ( P < 0.001). CONCLUSION This study suggests the presence of defective central antigen-independent and peripheral antigen-dependent checkpoints in patients with PR3-AAV, elucidating the selection process of autoreactive B cells. Trial registration ClinicalTrials.gov NCT00104299. Funding The Vasculitis Foundation, the National Institute of Allergy and Infectious Diseases of the NIH, and the Mayo Foundation for Education and Research.
Management of a Primary Retroperitoneal Yolk Sac Tumor
Shoukry, Mira , Kaplan, Jamie L. , Mangum, Catherine, Bagaria, Sanjay P. , Gabriel, Emmanuel , Mangum, Catherine A, Gabriel, Emmanuel M

Mayo Clinic

American Journal of Case Reports | October 7, 2021 | Volume: 22 | Issue: No issue available | Pages: No page available

10.12659/ajcr.933258 | PMID 34705815 Get It

Procainamide pharmacokinetics during extracorporeal membrane oxygenation
Vollmer, Nicholas , Wittwer, Erica D. , Rosenbaum, Andrew , Wieruszewski, Patrick M. , Vollmer, Nicholas J , Rosenbaum, Andrew N , Wieruszewski, Patrick M

Mayo Clinic

Perfusion | October 7, 2021 | Volume: 38 | Issue: 2 | Pages: 409-413

10.1177/02676591211050606 | PMID 34617854 Get It

Procainamide is a useful agent for management of ventricular arrhythmia, however its disposition and appropriate dosing during extracorporeal membrane oxygenation (ECMO) is unknown. We report experience with continuous procainamide infusion in a critically ill adult requiring venoarterial ECMO for incessant ventricular tachycardia. Pharmacokinetic analysis of procainamide and its metabolite, N-acetylprocainamide (NAPA), was performed using serum and urine specimens. Kidney function was preserved, and sequencing of the N-acetyltransferase 2 gene revealed the patient was a phenotypic slow acetylator. Procainamide volume of distribution and half-life were calculated and found to be similar to healthy individuals. However, despite elevated serum procainamide concentrations, NAPA concentrations remained far lower in the serum and urine. The magnitude of procainamide and NAPA discordance suggested alternative contributors to the deranged pharmacokinetic profile, and we hypothesized NAPA sequestration by the ECMO circuit. Ultimately, the patient received orthotopic cardiac transplantation and was discharged home in stable condition. Procainamide should be used cautiously during ECMO, with close therapeutic drug monitoring of serum procainamide and NAPA concentrations. The achievement of therapeutic NAPA concentrations while maintaining safe serum procainamide concentrations during ECMO support may be challenging.
Masks, Empathy, and a Pediatric Cancer Diagnosis During COVID-19
McCarthy, Sarah , Schiltz, Brenda , McCarthy, Sarah R. , McCarthy, Sarah R Brand, McCarthy, Sarah R , McCarthy, Sarah R.

Mayo Clinic

Pediatrics | October 7, 2021 | Volume: 148 | Issue: 5 | Pages: No page available

10.1542/peds.2021-051696 | PMID 34620726 Get It